The purpose of this study was to evaluate the association of the percentage of platelet inhibitory response to clopidogrel as assessed by modified thromboelastography with bleeding and transfusion requirement after offpump coronary artery bypass graft (OPCABG) surgery.
As dual antiplatelet therapy with aspirin and clopidogrel has become the cornerstone of the management of patients with coronary artery disease (1, 2) , an increasing number of patients undergoing coronary artery bypass graft (CABG) are at risk of irreversible platelet inhibition. Consequently, concerns for increased hemorrhagic complications after on-pump CABG have led to recommendations to stop the medications 5 days before elective surgery (3) (4) (5) .
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In view of post-operative blood loss, cardiopulmonary bypass has deleterious effects on the coagulation system and off-pump coronary artery bypass graft (OPCABG) has been proposed as an alternative surgical technique to reduce the risk of transfusion requirement in patients with recent exposure to antiplatelet therapy, but with conflicting results (6 -9) . This inconsistency may be attributable to the presence of substantial interindividual variability of clopidogrel responsiveness, which has not been considered previously in the surgical setting (10, 11) . Accordingly, the timing of surgery should be decided based on more objective findings encom-passing the individual variability of clopidogrel responsiveness and balancing the bleeding risk with the ischemic benefit.
For that purpose, platelet function assays have been used with prospective studies demonstrating close correlation between decreased clopidogrel responsiveness and increased ischemic complications after percutaneous coronary intervention (12) (13) (14) . However, no comprehensive data exist with regard to the association of increased bleeding and transfusion requirement with clopidogrel responsiveness after OPCABG.
We hypothesized that patients with recent exposure to clopidogrel undergoing OPCABG who display a high percentage of inhibitory response to clopidogrel as assessed by thromboelastography (TEG) platelet mapping assay (Haemoscope Corp., Niles, Illinois), regardless of the discontinuation date, are at increased risk of postoperative bleeding and the need for transfusion.
Methods
After institutional review board approval and informed consent were obtained, patients scheduled for isolated multivessel OPCABG between December 2007 and March 2009 were prospectively studied. The exclusion criteria were emergency (operation priority, including emergent or salvage OPCABG), myocardial infarction, history of cardiac surgery, history of bleeding diathesis or hepatic dysfunction, left ventricular ejection fraction Ͻ40%, hematocrit Ͻ33%, platelet count Ͻ100,000 mm 3 , abnormal range of prothrombin time and activated partial thromboplastin time, creatinine Ͼ1.4 mg/dl, and use of glycoprotein IIb/IIIa inhibitors ( Fig. 1) .
A total of 100 patients who were taking a daily oral regimen of aspirin 100 mg and clopidogrel 75 mg for at least 1 week were enrolled. The patients were divided into groups according to the discontinuation date of the dual antiplatelet therapy: aspirin and clopidogrel continued until 1 day before the surgery (n ϭ 50) and until 3 days before the surgery (n ϭ 50). The subdivision at 3 days before the surgery was according to the rate of platelet function recovery (15) and the results of previous studies performed during OPCABG (6, 7) .
Perioperative management of patients was according to institutional standards by a single team of anesthesiologists and cardiothoracic surgeons who were blinded to TEG platelet mapping assay results.
All surgical procedures were performed by 1 surgeon through a median sternotomy, and the heart was displaced using a posterior pericardial stitch, large (12 ϫ 70 cm) gauze swabs, and tissue stabilizer (Octopus Tissue Stabilization System, Medtronic Inc., Minneapolis, Minnesota). Systemic heparinization during anastomoses was achieved with 150 U/kg of porcine heparin, with additional doses given to reach the target activated clotting time of Ͼ300 s. On the completion of anastomoses, heparin activity was neutralized with protamine sulfate (0.5 mg/150 U of heparin). A cell salvage device was used during the surgery in all cases, and salvaged blood was reinfused in the patient before the end of the surgery. None of the patients received aprotinin or antifibrinolytics throughout the study period. All patients were transferred to the intensive care unit after the surgery.
Allogeneic packed red blood cells were transfused when the hematocrit level was Ͻ24% throughout the study period. Fresh frozen plasma was transfused when the postoperative international normalization ratio was Ͼ1.5 with excessive bleeding of Ͼ200 ml/h for 2 consecutive hours. The criteria for transfusion of platelets were post-operative platelet count Ͻ50,000/mm 3 with excessive bleeding of Ͼ200 ml/h for 2 consecutive hours. Surgical re-exploration was indicated when chest tube drainage was Ͼ200 ml/h for 6 consecutive hours or Ͼ400 ml during the first hour despite normalized activated clotting time and global coagulation status.
The hematocrit level, platelet counts, prothrombin time, and activated partial thromboplastin time were measured 24 h before and after the surgery. The total number of units of packed red blood cells, fresh frozen plasma, and platelets given during the post-operative hospitalization period were recorded, including the number of units given during the operation and in the intensive care unit post-operatively. Intraoperative blood loss was recorded as the amount of blood collected by a cell salvage device that was processed and reinfused. Post-operative blood loss was recorded as the volume of chest and mediastinal tube drainage measured 24 h after surgery and the drained blood was not reinfused. Dual antiplatelet therapy consisting of aspirin 100 mg and clopidogrel 75 mg was started 24 h after the surgery as adequate. Primary end points. The amount of post-operative blood loss and transfusion requirement were compared in relation to the tertile distribution of the percentage of platelet inhibitory response to clopidogrel measured by TEG platelet mapping assay. Blood sampling and TEG platelet mapping assay were performed immediately before the induction of anesthesia according to the manufacturer's recommendation, which are as follows. One milliliter of heparinized blood was transferred to a vial containing kaolin and mixed by inversion. Five hundred microliters of the activated blood were then transferred to a vial containing heparinase and mixed to neutralize the heparin. The neutralized blood (360 l) was added to a heparinase-coated cup and assayed in the TEG analyzer to measure the thrombin-induced clot strength. Heparinized blood (340 l) was added to a noncoated cup containing reptilase and activator F (factor XIIIa) to generate a whole-blood cross-linked clot in the absence Kwak et al. December 7, 2010 December 7, :1994 December 7, -2002 Clopidogrel Responsiveness and Bleeding in OPCABG Surgery of thrombin generation or platelet stimulation. A third sample (340 l) of heparinized blood was added to a nonheparinase-coated cup in the presence of the activator F and adenosine diphosphate (2 mol) or arachidonic acid (1 mmol/l) to generate a whole-blood cross-linked clot with platelet activation. The surgeon and anesthesiologists involved in patient management were blinded to the results of the TEG platelet mapping assay. Secondary end points. Evaluation of risk factors for the need for transfusion including the percentage of platelet inhibitory responses to the antiplatelet agents and discontinuation date was performed. In addition, the evaluation of 5 major morbidity end points and 30-day incidence of major adverse cardiac events was performed. The major morbidity end points were defined as permanent disability caused by stroke, renal dysfunction, any cardiac reoperation, prolonged ventilation Ͼ48 h, and deep sternal wound infection (16) . For clarification, renal dysfunction was defined as acute post-operative renal insufficiency resulting in Ն1 of the following: an increase of serum creatinine to Ͼ2.0 mg/dl; at least a 50% greater increase in creatinine above the baseline pre-operative value; and a new need for dialysis.
Major adverse cardiac events were defined as cardiac death, myocardial infarction, and revascularization. Post-operative myocardial infarction was defined as the occurrence of an increase in troponin-T Ն0.5 ng/ml (5 times the upper normal limit) and/or development of new pathologic Q-wave on the electrocardiogram (17) . Troponin T was evaluated 1 day before surgery and 12, 24, and 48 h after surgery. Statistical analysis. Statistical analyses were performed using SPSS version 13.0 (SPSS Inc., Chicago, Illinois). We determined that 84 patients would be required to detect a 250-ml difference in post-operative blood loss among the tertile of clopidogrel responsiveness with a standard deviation of 300 ml or 93 patients to detect a 2-fold increase in the incidence of transfusion requirement in the third tertile considering that 40% of the patients with similar characteristics required transfusion after OPCABG at an alpha level of 0.05 with 80% power (7). Continuous variables among the tertiles were compared by 1-way analysis of variance with Bonferroni post-hoc test. Continuous variables between the patients who were transfused or not were compared by the t test for normally distributed values; otherwise, the Mann-Whitney U test was used. Proportions were compared by the Fisher exact test or chi-square test as appropriate. The odds ratios and 95% confidence intervals investigating the independent predictive role of the percentage of platelet inhibitory responses to antiplatelet agents assessed by TEG platelet mapping assay on the transfusion requirement were assessed by logistic regression. The following parameters were first evaluated in the univariate model: age, female sex, pre-operative hematocrit, left main disease, discontinuation date of the antiplatelet agents, tertile distribution of platelet inhibitory response, and variables with p Ͻ 0.2 between patients who required transfusion or not. Only variables with p Ͻ 0.2 were then entered into the final model of multivariable logistic regression analysis. The ability of the TEG platelet mapping assay to discriminate patients who required transfusion or not was evaluated by receiver-operator characteristic curve analysis. The optimal cutoff value was defined as the point of the percentage of platelet inhibitory response providing the greatest sum of sensitivity and specificity. Categorical variables are expressed as number (%) and continuous variables are expressed as mean Ϯ SD, with p Ͻ 0.05 considered statistically significant.
Results
OPCABG could be successfully performed in all 100 patients without emergent conversion to on-pump CABG. Hemostatic re-exploration due to excessive bleeding was performed in 1 patient who had received clopidogrel therapy until the day before surgery. However, an obvious surgical bleeder was found, and thus data for this patient were excluded from statistical analyses.
Patient characteristics including the number of patients who stopped clopidogrel 1 day before surgery and the percentage of platelet inhibitory response to aspirin were all similar in relation to tertile distribution of the percentage of platelet inhibitory response to clopidogrel (Table 1) .
In the perioperative data, patients in the third tertile had a significantly greater amount of post-operative blood loss than those of the first and second tertiles. In addition, significantly more patients in the third tertile required packed red blood cells and fresh frozen plasma transfusion, and the number of units transfused was also significantly higher in patients in the third tertile than those in the first tertile (Table 2 ). Platelets were transfused in 2 patients each in the second and third tertiles during the post-operative period, and 6 U were transfused in each patient. Linear regression analysis between the percentage of platelet inhibitory response to clopidogrel and aspirin with post-operative blood loss resulted in R 2 values of 0.238 and 0.015, respectively.
Changes in troponin T and incidents of major adverse cardiac events and morbidity end points were similar in all tertiles except for the length of post-operative hospitalization, which was significantly longer in patients in the third tertile compared with those in the first and second tertiles (Table 3) .
In comparisons of patients who were transfused and those who were not (Table 4) , the discontinuation date of clopidogrel, the number of grafts performed, and the percentage of the platelet inhibitory response to clopidogrel met the predefined criterion of p Ͻ 0.2 and were further analyzed with logistic regression analysis with the previously cited risk factors for transfusion described in the Methods section. In univariate analysis of predictors of transfusion requirement, the discontinuation date of clopidogrel, tertile distribution of the percentage of the platelet inhibitory response, and the number of grafts performed had a p value Ͻ0.2. In multivariate analysis of these variables, only the highest tertile of the percentage of the platelet inhibitory response to clopidogrel remained an independent risk factor ( Table 5 ).
In the receiver-operator characteristic curve analysis, the percentage of the platelet inhibitory response to clopidogrel demonstrated an area under curve of 0.771 with a p value Ͻ0.001 and a 95% confidence interval of 0.674 to 0.868. Values are mean Ϯ SD or n (%). *p Ͻ 0.05. FFP ϭ fresh frozen plasma; pRBC(s) ϭ packed red blood cell(s).
Patient Characteristics in Relation to Tertile Distribution of the Percentage of Platelet Inhibitory Response to Clopidogrel
The optimal cutoff value for post-operative transfusion requirement was 70% platelet inhibitory response to clopidogrel with a sensitivity and specificity of 77.8% and 75.0%, respectively (Fig. 2) .
Discussion
This prospective, observational study demonstrates that patients with recent exposure to dual antiplatelet therapy who exhibited an increased percentage of platelet inhibitory response to clopidogrel, constituting the third tertile, were associated with significantly increased post-operative blood loss and subsequent transfusion requirement after elective multivessel OPCABG. Moreover, only the tertile distribution of the percentage of platelet inhibitory response to clopidogrel remained an independent risk factor for transfusion requirement, irrespective of the discontinuation date of antiplatelet therapy.
With increased clinical application of dual antiplatelet therapy consisting of aspirin and clopidogrel, the potential hemorrhagic complications arising from the use of these , 2010:1994-2002 Clopidogrel Responsiveness and Bleeding in OPCABG Surgery agents in proximity to the CABG have become a major issue. Indeed, numerous studies have reported increased periprocedure blood loss and the need for transfusion, hemostatic re-exploration, and resource utilization after CABG in patients with recent exposure to clopidogrel (18 -20) . At the same time, it has also become well established that the platelet inhibitory response to clopidogrel varies substantially among individuals (10, 11) . Prospective studies using various platelet function monitoring methods have demonstrated an association between the lack of a pharmacodynamic effect of clopidogrel and ischemic events after percutaneous coronary intervention, which also appears to have a dose-response relationship (12) (13) (14) . These observations argue against the current uniform approach of drug cessation for Ն5 (preferably 7) days to patients exposed to clopidogrel who require surgery. Although no comprehensive data exist, the platelet function assay in this context may provide an objective guideline allowing the elimination of unnecessary delay of surgery while maximizing the ischemic benefit. By avoiding cardiopulmonary bypass, OPCABG has been demonstrated to be a significant factor associated with reduced transfusion requirement regardless of recent clopidogrel exposure and has been proposed as an alternative surgical technique to reduce hemorrhagic complications (6, 7, 9) . Therefore, OPCABG provides an excellent model with which to assess the clinical utility of platelet function assay when assessing post-operative blood loss and transfusion requirement because it is devoid of a major confounding variable on the coagulation system, cardiopulmonary bypass (21, 22) .
1999
As the results of this current study indicate, patients in the third tertile of the percentage of platelet inhibitory response to clopidogrel had a significantly greater postoperative blood loss compared with those in the first and second tertiles. Consequently, a significantly greater number of patients in the third tertile of the percentage of platelet inhibitory response to clopidogrel required transfusion of packed red blood cells and fresh frozen plasma, and a longer length of post-operative hospitalization. Furthermore, patients in the third tertile of the percentage of platelet inhibitory response to clopidogrel had an 11-fold increased risk of requiring transfusion of allogeneic blood products. Blood transfusion in cardiac surgery has been clearly demonstrated to be associated with increased length of hospital day, in-hospital mortality, and long-term mortality, especially after CABG (23, 24) . In contrast to the results of previous studies assessing the relationship between clopidogrel exposure and post-operative blood loss without using platelet function assay (6,18 -20) , the discontinuation date of clopidogrel was not associated with increased blood loss or transfusion requirement in the current trial. Although a different method of platelet function assay (light transmittance aggregometry) was used in a limited number of patients (n ϭ 45) undergoing CABG, with an emphasis on the importance of a strict transfusion algorithm, similar results had been found in a previous study in which patients with clopidogrel-induced platelet inhibition Ն60% had a significantly greater transfusion requirement (25) . The result that the percentage of platelet inhibitory response to aspirin was not associated with increased blood loss or transfusion requirement is also in accordance with the results of a previous study demonstrating no influence of continuous aspirin on bleeding complications after either isolated on-pump, off-pump, or repeat CABG (26) . Among the platelet function assays used in clinical practice, TEG platelet mapping assay enables quantitative analysis of hemostatic status and platelet function as well (27) . Although manual pipetting of reagents and a blood sample are required, it has been demonstrated to be reliable with low analytical variation (28) . Clinically, it has also been demonstrated to be able to discriminate patients with subsequent ischemic events after percutaneous coronary intervention (13) . In that study, the percentage of platelet inhibitory response Ͻ30% provided a positive predictive value of 73% and negative predictive value of 91% for the combined ischemic outcome. In the current study, the TEG platelet mapping assay could also provide a cutoff value of the percentage of platelet inhibitory response to clopidogrel for transfusion requirement after OPCABG by receiveroperator characteristic curve analysis, which was 70% with a sensitivity and specificity of 77.8% and 75.0%, respectively. As patients in the third tertile exhibited significantly increased post-operative blood loss and subsequent transfusion requirement as well as longer post-operative hospitalization, TEG platelet mapping assay may provide clinically useful information concerning the timing of surgery.
Bleeding and subsequent transfusion requirement after CABG are multifactorial, with potential risk factors including age, female sex, chronic renal failure, hemodialysis, poor left ventricular ejection fraction, left main disease, and pre-operative anemia (9) . Moreover, a recent study demonstrated that the strongest factor associated with transfusion was which surgeon performed the CABG (29) . Thus, to validate the association of platelet inhibitory response to clopidogrel assessed by a platelet function assay with postoperative bleeding and transfusion requirement, confounding variables should be controlled as much as possible, as in the current trial. Study limitations. This, in turn, however, invariably confronts generalization of the observed results, which is a limitation of this study, and the results of this study should not be extended to other subsets of patients at increased risk of bleeding or undergoing on-pump CABG. Another limitation of this study is that, although the statistical power of the third tertile as the only independent predictor is sufficient, the introduction of 3 predictors to the multivariate logistic regression analysis overfits the model because the sample size was calculated to validate the primary end points of this study.
